Enliven Therapeutics, Inc. (ELVN)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$59.32-0.55%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Intact: The reason to own it still holds.
Enliven is advancing its cancer drug trials steadily. The company raised nearly 9 million shares to fund growth. Operating losses improved from -$34.3M to -$27.8M recently. Upcoming trial data could boost valuation.
Enliven remains loss-making with no revenue yet. Leadership changes and insider selling raise concerns. Cash burn control progress is limited. Negative EPS is expected to continue.
The stock trades about 18% below our $62 fair value, in line with the Street median. The market expects continued losses and slow growth, while we see potential upside from clinical progress.
Breaks if: failure to complete planned capital raise
Manage capital prudently, including upsized public offering and debt issuance to strengthen balance sheet and extend cash runway.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity, given its focus on advancing clinical trials while currently facing financial losses. The thesis is in a watch state, reflecting mixed recent performance and ongoing management priorities.
The market seems to have a low fragility tier, indicating that it does not expect significant volatility in the near term. However, the current valuation reflects the company's loss-making status and the elevated risks in the healthcare sector.
Management has made progress in clinical development and capital allocation, but the recent financial performance has been weak. The company continues to face significant cash burn and net losses, which could impact its operational stability.
The future of ELVN depends on the performance of sector bellwethers and the overall healthcare market. If these companies continue to perform well, it could provide a favorable environment for ELVN, while any downturn could pose risks.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The latest earnings miss contributed to this change. The company reported a significant miss of 29% on its recent earnings. This performance raises concerns about its financial trajectory.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated in 2 of last 3 quarters. Cash position increased from $452 million in 2026-Q1 to $895 million in 2026-Q2, reflecting the upsized public offering raising approximately $400 million. Management has maintained disciplined capital allocation with a strengthened balance sheet, delivering on stated priorities.
“Strong balance sheet with $895 million in cash, cash equivalents and marketable securities.”
“Announced upsized public offering of common stock expected to raise approximately $400 million.”
Breaks if: failure to meet expected clinical milestones or trial setbacks
Continue progressing clinical trials and development programs for Enliven's therapeutic candidates to achieve clinical milestones.
Breaks if: operating loss worsens beyond -$27.8M
Manage research and development and general administrative expenses to control net loss and cash burn.
Stated in 3 of last 3 quarters. Operating expenses increased with R&D rising from $20.7 million in 2026-Q1 to $29.0 million in 2026-Q2, and net loss increased from $23.6 million to $32.5 million. Management continues to control expenses but net loss and cash burn remain significant, indicating ongoing operational cost management.
“R&D expenses were $29.0 million and G&A expenses were $8.2 million for the second quarter of 2026.”
“R&D expenses were $20.7 million and G&A expenses were $7.1 million for the first quarter of 2026.”
“Operating expenses were $28.6 million for the fourth quarter of 2025.”
Over the next 1 to 3 years, ELVN's prospects will largely depend on its clinical advancements and the broader healthcare sector's performance. Not investment advice.